74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Theravance Biopharma Inc
Closed
9.31 -3.32
Overview
Share price change
24h
Min
9.3
Max
9.39
Income | 3.8M -13M |
|---|---|
Sales | 2.6M 17M |
EPS | -0.059 |
Profit margin | -75.279 |
Employees | 99 |
EBITDA | 4.9M -8.7M |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | 479M |
|---|---|
Previous open | 12.63 |
Previous close | 9.31 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Theravance Biopharma Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Theravance Biopharma Inc Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
